Analysis of Preclinical and Clinical Samples After Treatment With a CD37 Targeting Antibody Drug Conjugate (AGS67E) Support a High Level of CD37 Expression in NHL

Hematological Oncology - United Kingdom
doi 10.1002/hon.2439_20
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

AGS67E, an Anti-Cd37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML

Molecular Cancer Therapeutics
Cancer ResearchOncology
2015English

Preclinical Evaluation of a GFRA1 Targeted Antibody-Drug Conjugate in Breast Cancer

Oncotarget
Oncology
2018English

A Regulatory Role for CD37 in T Cell Proliferation

Journal of Immunology
AllergyImmunology
2004English

Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models

Cancer Research
Cancer ResearchOncology
2016English

Targeting B-Cell Malignancies With the Beta-Emitting Anti-Cd37 Radioimmunoconjugate 177Lu-Nnv003

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2019English

SGN-LIV1A: A Novel Antibody-Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer

Molecular Cancer Therapeutics
Cancer ResearchOncology
2014English

Targeting the Fcμ-Receptor in Chronic Lymphocytic Leukemia With a Novel IgM-derived Antibody-Drug Conjugate

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2013English

A Complementary Role for the Tetraspanins CD37 and Tssc6 in Cellular Immunity

Journal of Immunology
AllergyImmunology
2010English

Intracellular Catabolism of an Antibody Drug Conjugate With a Noncleavable Linker

Drug Metabolism and Disposition
PharmacologyPharmaceutical Science
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy